Key facts
- It has raised $68.0M; the latest was Later Stage VC ($33.0M) in Dec 2024.
- Notable investors include Puhua Capital, Cambridge Angels, Cambridge Enterprise Ventures, Amadeus Capital Partners, Meltwind Advisory — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Natrox
- ·The full record, as it builds
Funding rounds
No funding rounds for Natrox are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Natrox
Developer of a wound therapy device designed to improve the quality of life for patients with chronic wounds. The company uses artificial intelligence to analyze captured wound images and track healing progression and offers a battery-operated oxygen-generating device that delivers a continuous stream of pure humidified oxygen directly to the wound bed, improving the healing of chronic wounds such as diabetic foot ulcers, pressure ulcers, and arterial and venous leg ulcers, enabling clinicians to track a patient's treatment and communicate in real-time.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2003
- Employees
- 37
- Website
- natroxwoundcare.com/
- Ownership
- Privately Held (backing)
Natrox doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Natrox shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Natrox in its N-PORT filings yet. We sweep new filings monthly.